The problem starts in your stomach. You swallow a capsule of curcumin—the golden compound extracted from turmeric and pitched as everything from an anti-inflammatory to a cognitive booster—and expect results. What you get instead is an expensive trip through your digestive tract, most of the active ingredient passing straight through, never entering your bloodstream, never reaching the tissues where it might actually do something.
This isn't a secret, exactly. Anyone who's spent time around supplement formulation knows that bioavailability—the fraction of an ingested compound that makes it into circulation—is the industry's chronic engineering nightmare. Curcumin is a notorious offender, but it has plenty of company: resveratrol, quercetin, a whole catalog of plant-derived molecules that sparkle in the petri dish and disappoint in the body.
For years, the industry has applied Band-Aids. Add black pepper extract to enhance bioavailability by inhibiting drug metabolism. Wrap compounds in synthetic surfactants. Or just crank up the dose and hope enough squeaks through. These fixes work, sort of, but they're inelegant. Some raise safety flags. All of them sidestep the root issue: coaxing hydrophobic molecules to dissolve and slip across the gut wall.
Now a German biotech called EVANIUM Healthcare, based in Regensburg, believes it has cracked the code. The company announced a €2.2 million seed round in April 2026, funding earmarked for clinical trials of OPTISOLV—a dual-coating delivery system that the company claims can boost absorption by orders of magnitude. In some formulations, more than 1,000-fold.
That would be remarkable, if true. It would also be lucrative.
Sand in Your Supplements
The nutraceuticals market is hurtling toward $1.15 trillion by 2033, according to projections from Grand View Research. Yet efficacy—the inconvenient question of whether supplements actually deliver what their labels promise—remains a persistent sore spot. A consumer reaches for curcumin hoping for joint relief. Most of what they swallow never gets absorbed. The story repeats across polyphenols, flavonoids, and a roster of botanicals whose therapeutic potential is constrained by lousy solubility.
This gap has spawned an entire sub-industry of bioavailability enhancers, a market for ingredients that make ingredients work. According to a February report from Future Market Insights, the nutraceutical excipients sector is expected to nearly double from $2.8 billion in 2025 to $5.2 billion by 2035, driven by demand for clean-label innovation and measurable outcomes.
Several enhanced curcumin products already crowd store shelves. Indena's Meriva, a phospholipid complex, has claimed roughly 30-fold absorption gains in studies still cited in marketing materials. NovaSOL, a micellar formulation, references 185-fold improvements in area under the curve and 455-fold in peak blood concentration, data drawn from a 2014 human trial. Longvida's solid lipid platform touts somewhere between 67- and 285-fold bioavailability increases, depending on how you slice the math. CAVACURMIN, a gamma-cyclodextrin complex, points to a 40-fold boost traced back to a 2013 crossover study.
The numbers swing wildly because studies measure different endpoints—total curcuminoids versus free forms, area under the curve versus peak levels, dose-adjusted or not. An independent 2025 trial in nine healthy men underscored the messiness, making clear that standardized pharmacokinetic metrics are badly needed when brands stake claims.
Pressure Points
Three forces are reshaping how supplements get made. First, regulatory tightening. The European Union banned titanium dioxide in food supplements back in January 2022, forcing reformulations away from synthetic coatings. In March 2024, Spain's food safety agency noted that high-bioavailability formats like micellar curcumin "could be considered novel food" if absorption diverges enough from historical use—a signal that drastically enhanced delivery might trigger extra scrutiny.
Second, consumer pickiness. Shoppers increasingly balk at synthetic emulsifiers, polysorbates, and piperine (black pepper extract), the latter raising concerns about drug interactions through enzyme inhibition. Brands want efficacy, but not at the cost of ingredient lists that read like organic chemistry finals.
Third, enforcement muscle. The FTC's December 2022 Health Products Compliance Guidance—still in force—requires "competent and reliable scientific evidence" for performance claims, typically meaning randomized controlled human trials. Companies that want to advertise superior bioavailability need the data to back it up, not just lab-bench studies.
Enter OPTISOLV. The platform stacks two layers: an inner cyclodextrin inclusion complex that solubilizes hydrophobic actives, wrapped in an outer shell of sunflower lecithin and starch. Cyclodextrins are ring-shaped molecules that trap poorly soluble compounds in their hydrophobic core, nudging them toward water compatibility. The phospholipid coating stabilizes these complexes, preventing them from clumping back together and easing their passage through the gut wall. Both gamma-cyclodextrin and lecithin are authorized in the EU—gamma-CD as a novel food since 2012, lecithin cleared by EFSA evaluations in 2017 and 2020.
EVANIUM's published in-vitro data for OPTISOLV curcumin shows more than 1,000-fold increased water solubility and up to 170-fold greater release under simulated intestinal conditions, compared to native curcumin. Those are dissolution numbers, not human pharmacokinetics—a distinction that matters. As of April 2026, EVANIUM hasn't posted public human PK data in journals or on its site. The company says clinical validation is a priority for the fresh capital.
From Lab to Pharmacy Shelf
EVANIUM was founded in 2019 and currently employs 12 people at its Regensburg office in Bavaria. The company holds four patents covering the delivery architecture. Co-founder and CTO David Ofner comes from a pharma background; CEO Felix Rolka brings degrees in international entrepreneurship and an MBA. The investor roster includes veterans from Boehringer Ingelheim, Ratiopharm, and specialty pharma outfits.
The company has productized four actives under the OPTISOLV line so far: curcumin, berberine, boswellia, and passiflora. The ambition is broad—nutraceuticals, functional foods, nutricosmetics, pharma applications—though that scope depends on proving clinical performance across categories.
The first major commercial validation arrived in October 2025, when Hevert-Arzneimittel, a German pharmaceutical firm, launched Curcumin Hevert OPTISOLV into pharmacies. The product markets itself on "1,000-fold better solubility" versus conventional turmeric extract and explicitly skips piperine and polysorbates, listing gamma-cyclodextrin and sunflower lecithin among the excipients instead. Hevert's product page emphasizes vegan capsules and clean formulation.
It's a case study in differentiation by omission. By avoiding piperine—which some competitors use to throttle curcumin metabolism—Hevert sidesteps potential drug-interaction worries for customers juggling multiple medications. The partnership hands OPTISOLV real pharmacy distribution and a reference customer in a regulated sales channel, not just the Wild West of online supplement retail.
The April seed round, led by Berlin's FoodLabs and Munich's Feast Ventures, is earmarked for clinical validation, expanding the ingredient portfolio beyond four actives, and pushing the platform into international markets. That's a revealing priority list. The company is moving from promising test-tube results to the human trials that will either validate the technology or expose its limits.
The Proof Will Be in the Bloodwork
The OPTISOLV story sits at a crossroads. Nutraceutical excipients are the fastest-growing slice of the broader ingredients market, propelled by the need for bioavailability, stability, and formulations that don't scare consumers. A mid-2025 industry report pegged the U.S. market around $1.3 billion, with China showing the steepest growth trajectory through 2030, driven by multi-functional excipients and clean-label pressure.
Academic literature is catching up. A 2025 review in the Journal of Liposome Research surveyed liposomes incorporating cyclodextrins to boost drug delivery. A 2026 paper in Food Hydrocolloids described dual-encapsulated gamma-cyclodextrin liposomal hydrogel beads for controlled lutein delivery, demonstrating the feasibility of "drug-in-CD-in-liposome" architectures. The science supports the concept. The question is execution and cost at commercial scale, and whether the numbers hold up when humans swallow the capsules.
For formulators and investors watching this space, a few tripwires stand out. First, the gap between dissolution data and what happens in living bodies. In-vitro multiples don't always translate directly to blood-level improvements, as competing curcumin platforms have discovered. EVANIUM's clinical work will need to bridge that gap with head-to-head human trials, not just simulations.
Second, regulatory pathways. High-bioavailability variants may face novel food scrutiny in parts of Europe if absorption swings too far from traditional use, as Spain's stance on micellar curcumin showed. Navigating that will require jurisdiction-specific dossiers and possibly new safety studies, adding time and expense to rollouts.
Third, competitive dynamics. Enhanced bioavailability is no longer exotic—it's table stakes in premium supplements. OPTISOLV's dual-coating approach offers a clean-label hook and striking in-vitro numbers, but it will collide with established brands that have years of clinical and commercial momentum. Price, formulation flexibility, and the robustness of human data will determine whether OPTISOLV becomes an industry standard or a niche play.
The broader opportunity is undeniable, though. Personalization and what analysts call "intelligent delivery systems" are being flagged as differentiators for the next decade. Consumers increasingly want proof, not just promises. Brands that can demonstrate measurable absorption gains with transparent, clean formulations stand to capture premium pricing and loyalty in a market expanding faster than most.
EVANIUM's next year or so will clarify whether OPTISOLV can deliver on that potential. The seed funding buys runway for the trials that actually matter. If the human data confirms the test-tube story—and if the company can scale production without blowing up cost or quality—the dual-coating architecture could reset expectations for what botanical supplements can realistically achieve. If not, it joins a long parade of technologies that sparkled in the lab and stumbled somewhere between the beaker and the clinic.
